Janux Q1 net loss $17.5M; first patient dosed with JANX008 in Phase 1

Janux Therapeutics, Inc.

2023-Q1 EPS reported -$0.42 revenue$2,048,000

Cash and equivalents $316.9M, down from $327.0M at Dec 31, 2022.
R&D expenses $15.9M (up from $10.2M); G&A $6.5M (up from $4.9M).
First patient enrolled in EGFR-TRACTr (JANX008) Phase 1 for solid tumors.
Interim clinical update for PSMA-TRACTr (JANX007) expected in 2H 2023.
PD-L1xCD28 TRACIr (JANX009) IND on track for submission in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Janux Therapeutics, Inc. reported the three months ended March 31, 2023 results: net income net loss of $17.5 million.

Period: the three months ended March 31, 2023
Net income: net loss of $17.5 million
Result: reported results

Exact text from the filing

On May 9, 2023, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-019641

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.